Trial Profile
An Open-Label Clinical Study Evaluating the Long Term Safety of ALTU-135 in the Treatment of Patients With Exocrine Pancreatic Insufficiency Due to Chronic Pancreatitis or Pancreatectomy
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Liprotamase (Primary)
- Indications Exocrine pancreatic insufficiency; Pancreatitis
- Focus Adverse reactions
- Acronyms DIGEST CP
- Sponsors Alnara Pharmaceuticals
- 28 May 2014 New trial record